Zonisamide: adverse event reports filed with FDA

4,885

reports as suspect product

0% of all reports · about 219 a year

363

reports, 12 months to June 2026

415 in the 12 months before

87.3%

marked serious by the reporter

78.1% across the class

7%

record death among outcomes, as reported

344 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Zonisamide reports recording the termmedian drug in anti-epileptic agent

1. Drug ineffectivethe medicine did not work as expected17.6%862
2. Seizurea fit or convulsion8.4%409
3. Off label useused for a purpose or in a way not on the label7.9%387
4. Multiple-drug resistance4.9%240
5. Foetal exposure during pregnancythe unborn baby was exposed to the medicine4.6%227
6. Drug interactionan interaction between medicines4.1%201
7. Somnolencedrowsiness4%197
8. Fatiguetiredness3.9%190
9. Condition aggravatedthe condition being treated got worse3.7%179
10. Dizzinesslight-headedness or unsteadiness3.4%168
11. Treatment failurethe treatment did not work3.3%160
12. Epilepsy3.1%151
13. Convulsion3%148
14. Vomitingbeing sick2.9%141
15. Nauseafeeling sick2.9%140
16. Status epilepticus2.8%136
17. Drug reaction with eosinophilia and systemic symptomsDRESS, a severe reaction with rash, fever and organ involvement2.7%134
18. Product use in unapproved indicationused for a purpose not on the label2.7%134
19. Recalled product administered2.7%134
20. Cognitive disorderproblems with thinking or memory2.7%131
21. Headachehead pain2.7%130
22. Rashskin rash2.3%111
23. Drug resistance2.2%106
24. Ataxia2.1%104
25. Pyrexiafever2.1%104
26. Depressionlow mood2.1%101
27. Weight decreasedweight loss2%97
28. Aggressionaggressive behaviour2%96
29. Generalised tonic-clonic seizure1.9%93
30. Insomniadifficulty sleeping1.8%88

Top 30 of 838 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 23 drugs in the anti-epileptic agent class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 269,757 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 42.1% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,885 reports.

Drugs most often listed in the same reports

Other products listed in reports where Zonisamide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the anti-epileptic agent class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Zonisamide as a suspect or interacting product; reports listing it only as a concomitant medication (5,750) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.